Market Currents

• Tuesday, September 29, 2009

• 12:05 PM Regenerx Biopharmaceuticals (RGN) jumps 64% after researchers demonstrate for the first time that Tb4 treatment of EAE (an animal model for MS) significantly improves neurological functional recovery. Much of RGN's product development is based on Tb4. (PR) Comment!